<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cy--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17353926</article-id><article-id pub-id-type="pmc">2360129</article-id><article-id pub-id-type="pii">6603644</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6603644</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Neri</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pantaleo</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Giommoni</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Grifoni</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Paoletti</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rotella</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pantalone</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Taddei</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mercatelli</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tonelli</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Department of Oncology, Centre of Experimental and Clinical Oncology, University of Florence</institution> Florence, <country>Italy</country></aff><aff id="aff2"><label>2</label><institution>Unit of General Surgery, Department of Critical Medicine, University of Florence</institution> Florence, <country>Italy</country></aff><aff id="aff3"><label>3</label><institution>Unit of General Surgery, &#x02018;Azienda Ospedaliero-Universitaria Careggi'</institution> Florence, <country>Italy</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:bruno.neri@unifi.it">bruno.neri@unifi.it</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>03</month><year>2007</year></pub-date><pub-date pub-type="collection"><day>03</day><month>04</month><year>2007</year></pub-date><pub-date pub-type="ppub"><day>10</day><month>04</month><year>2007</year></pub-date><volume>96</volume><issue>7</issue><fpage>1043</fpage><lpage>1046</lpage><history><date date-type="received"><day>15</day><month>05</month><year>2006</year></date><date date-type="rev-recd"><day>24</day><month>01</month><year>2007</year></date><date date-type="accepted"><day>29</day><month>01</month><year>2007</year></date></history><copyright-statement>Copyright 2007, Cancer Research UK</copyright-statement><copyright-year>2007</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>The association between oxaliplatin and 5-fluorouracil (5-FU) has been extensively reported to improve prognosis of gastric cancer patients. The present study is aimed at evaluating response rate and the toxicity profile of the association with oxaliplatin, 5-FU/lecovorin and epirubicin in gastric cancer patients with locally advanced or metastatic disease. Thirty-six patients have been enrolled and 35 evaluated. The treatment schedule was oxaliplatin (100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>), 5-FU (400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>), leucovorin (40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) and epirubicin (60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) intravenously. administered every 3 weeks for 6 months, for a total of 185 therapy cycles . Response rate and toxicity were assessed according to the international WHO criteria. Every patient received a mean of 5.3 therapy cycles in a day-hospital setting. Sixteen of 35 patients (46&#x00025;) showed an objective response, two complete response and 14 partial response. Median time to progression was 33 weeks with an overall median survival of 49 weeks. During the study, anaemia grade 3 and neutropenia grade 3 were observed in 9 and 11&#x00025; of patients respectively. A grade 3 periferic sensorial neuropathy was observed in 6&#x00025; of patients. No life threatening or cardiac toxicity was recorded. The regimen used showed anticancer activity against gastric carcinoma, a tolerable toxicity profile and excellent patient compliance.</p></abstract><kwd-group><kwd>chemotherapy</kwd><kwd>epirubicin</kwd><kwd>5-fluorouracil</kwd><kwd>gastric cancer</kwd><kwd>leucovorin</kwd><kwd>oxaliplatin</kwd></kwd-group></article-meta></front><body><p>Gastric cancer is the second most frequent tumour worldwide and one of the most frequent causes of cancer-related deaths. Although the incidence and mortality for gastric cancer are decreasing in many countries and in spite of important changes in the therapeutic options over the last decade, gastric cancer still represents the second most frequent malignancy in the world and the fourth in Europe (<xref ref-type="other" rid="bib13">Parkin <italic>et al</italic>, 2001</xref>), with a poor prognosis even at an early stage of the disease. Also, patients with gastric cancer typically present with advanced disease. For patients presenting with an earlier stage of disease, more than 50&#x00025; undergo surgery, but even after a curative resection, 60&#x00025; eventually relapse locally or with distant metastases with a median survival time of 4&#x02013;6 months, that may improve up to 7&#x02013;10 months with a chemotherapy regimen. Although early diagnosis is the mainstay of successful treatment, even if radically treated, about 50&#x00025; of patients present a disease relapse or spread within 5 years from diagnosis (<xref ref-type="other" rid="bib19">Wilke <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib18">Wagner <italic>et al</italic>, 2005</xref>). Hence, in locally advanced or metastatic disease, the only available choice appears to be systemic chemotherapy (<xref ref-type="other" rid="bib9">Macdonald <italic>et al</italic>, 1979</xref>; <xref ref-type="other" rid="bib14">Preusser <italic>et al</italic>, 1989</xref>; <xref ref-type="other" rid="bib18">Wagner <italic>et al</italic>, 2005</xref>), that has proved to improve survival compared with supportive care alone (hazard ratio (HR): 0.39; 95&#x00025; confidence interval (CI): 0.28&#x02013;0.52). Combination therapy regimens were found more effective than single-agent therapies, particularly 5-fluorouracil (5-FU), (HR: 0.85; 95&#x00025; CI:0.76&#x02013;0.96). Among polychemotherapies those containing the combination with cisplatin (DDP), 5-FU and antracycline derivatives proved more effective than those without antracyclines (HR: 0.77; 95&#x00025; CI: 0.62&#x02013;0.95) suggesting that polychemotherapy may significantly improve survival among patients with advanced stage gastric cancer. Recognition of epirubicin's (EPI) activity in gastric cancer and its better toxicity profile, compared with doxorubicin (<xref ref-type="other" rid="bib5">Launchbury and Habboubi, 1993</xref>), have led to incorporate it into combination regimens for advanced gastric cancer. In the last decade, oxaliplatin (L-OHP), a third-generation platinum derivative, has been found to represent an intriguing alternative to cisplatin, as it shows a comparable activity but a more favourable global toxicity profile (<xref ref-type="other" rid="bib11">Misset <italic>et al</italic>, 2000</xref>). Moreover, because 5-FU is considered a cornerstone of therapy for gastric cancer, combining it with L-OHP is logical, and there is considerable evidence of preclinical synergy between the two agents (<xref ref-type="other" rid="bib15">Raymond <italic>et al</italic>, 1998</xref>). Clinical studies with L-OHP&#x02013;5FU-based regimen reported a high response rate ranging from 43 to 55&#x00025; in the treatment of gastric cancer and an excellent toxicity profile (<xref ref-type="other" rid="bib1">Al Batran <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib2">De Vita <italic>et al</italic>, 2005</xref>).</p><p>On the basis of these data, we designed this phase II study to determine the response rate and toxicity profile of the combination chemotherapy of L-OHP&#x02013;5FU/LV&#x02013;EPI as first-line treatment in locally advanced and/or metastatic gastric cancer.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Eligibility</title><p>From December 2001 to November 2003, 36 patients with histologically proven gastric cancer, locally unrecsectable, recurrent after surgery or with metastatic localisations entered the study, after being thoroughly informed of the study design, benefits and risks according to the guidelines of local ethic committee and the Declaration of Helsinki Principles, and all of them signed their consent. All patients had measurable disease and met the following criteria: performance status (ECOG)&#x02a7d;2, life expectancy of at least 3 months and age &#x02a7d;75 years . Laboratory acceptance parameters included a white blood cell count above 4000&#x02009;cells&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, a haemoglobin level not lower than 9.5&#x02009;g&#x02009;dl<sup>&#x02212;1</sup>, a platelet count not less than 100&#x02009;000&#x02009;<italic>&#x003bc;</italic>l<sup>&#x02212;1</sup>, serum transaminase &#x0003c;3 &#x000d7; the upper normal limit (UNL) and bilirubin and creatinine values of &#x0003c;1.5 &#x000d7; UNL. Contraindication to entry included an active infectious process, an active heart disease, central nervous system involvement or any concomitant second primary cancer. Patients who had received previous chemotherapy were also excluded.</p></sec><sec><title>Pretreatment evaluation</title><p>History, full-body examination and tumour-related symptoms were recorded for each patient. Further assessment included vital sign examination, performance status determination and laboratory tests (haematology, blood chemistry and urinalysis). At study entry the following investigations were obligatory performed: bone scintigraphy, ECG, echocardiogram with evaluation of ventricular function, chest X-ray, abdominal ultrasound, computed tomography (CT) and, only if indicated, CT scan of the thorax.</p></sec><sec><title>Treatment schedule and dose modifications</title><p>Oxaliplatin (100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>), 5-FU (400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>), LV (40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) and EPI (60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) were administered intravenously, on an outpatient basis. The treatment was repeated every 3 weeks or until evidence of disease progression, patient refusal or unacceptable adverse reactions. The overall treatment was programmed over a 6 month period (maximum eight cycles), considering that the risk of developing severe disturbance of neurologic function is related to L-OHP neurotoxicity, that generally becomes a clinical problem when the cumulative dose approximates 800&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (<xref ref-type="other" rid="bib3">Extra <italic>et al</italic>, 1998</xref>). Full doses of the anticancer drugs were given if granulocyte count was &#x0003e;1500&#x02009;<italic>&#x003bc;</italic>l and platelet count was &#x0003e;100&#x02009;000&#x02009;<italic>&#x003bc;</italic>l. In the case of grade 2 or more toxicity excepted alopecia, chemotherapy was discontinued for a week and than restarted after full recovery. During the study, leukocite-stimulating growth factors were allowed in patients showing grade 3 or more neutropenia. Reduction of 25&#x00025; in all the drugs dose was performed in the event of a second consecutive occurrence of grade &#x0003e;2 toxicity. Patients with unsolved grade 2 or more toxicity after two consecutive treatment delays or experiencing grade 3 and 4 nonhaematological toxicity except alopecia went off study.</p></sec><sec><title>Treatment response and toxicity</title><p>For evaluation of tumour response, the best objective imaging technique for the each individual patient was decided following pretreatment evaluation (either CT scan, ultrasound or conventional X-ray imaging). The same technique was then performed every 6 weeks by the same investigator and tumour response was assessed together with a second independent radiologist.</p><p>All the patients were thereafter examined the 15th day of every cycle and before the start of every following cycle. Toxicity and response rate were assessed and evaluated according to the <xref ref-type="other" rid="bib21">WHO criteria (1979)</xref>.</p></sec><sec><title>Statistical methods</title><p>According to the optional Simon two-step design, if a minimum objective response rate &#x0003e;40&#x00025; was observed in the first 15 patients, an additional 15 patients were enrolled and if &#x0003e;12 responses were observed in 30 patients (40&#x00025;), the regimen was considered active and submitted for further evaluation (<xref ref-type="other" rid="bib16">Simon, 1989</xref>). The descriptive statistics were reported as proportions and medians. Time to disease progression (TTP), was defined as the interval between initial treatment and the time of disease progression or death. Survival time was calculated from the date of treatment initiation until the date of the last follow-up evaluation or death. TTP and overall survival (OS) were analysed according to the Kaplan&#x02013;Meier method (<xref ref-type="other" rid="bib4">Kaplan and Meier, 1958</xref>). The CIs for response rates, TTP and OS were calculated using methods for exact binominal CI (<xref ref-type="other" rid="bib7">Lentner, 1982</xref>) . Survivors were censored on the last date they were known to be alive.</p></sec></sec><sec><title>RESULTS</title><p>From December 2001 to November 2003 a total of 36 patients (25 male, 10 female patients, age range 39&#x02013;72 years, mean age 58 years) were enrolled. Among them, one patient denied consent to undergo the second treatment and dropped out from the study. Among the 35 patients who completed the study and were evaluated for the above mentioned parameters, 27 (77&#x00025;) had a performance status up to 1. Twenty-four of 35 had undergone surgery before the study. The large majority of patients had a metastatic disease (21/36; 58&#x00025;), with a high prevalence of nodal or hepatic disease spread (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p><p>Patients received a total amount of 185 therapy cycles (5.3 cycles/patient, range 2&#x02013;8). At the end of the study, two patients experienced complete response (6&#x00025;) and 14 partial response (40&#x00025;). The overall response rate was 46&#x00025; (95&#x00025; CI: 30.2&#x02013;63.8), with a median disease-free survival time of 27 weeks (95&#x00025; CI: 20&#x02013;31; range 7&#x02013;104&#x0002b;).</p><p>Among the other patients, 13 patients showed a stable disease (37&#x00025;) whereas six patients presented disease progression (17&#x00025;). The median time to disease progression was 33 weeks (95&#x00025; CI: 17&#x02013;49; range 6&#x02013;104&#x0002b;) with a median survival time of 49 weeks (95&#x00025; CI: 32&#x02014;66; range 9&#x02013;104&#x0002b;) (<xref rid="tbl2" ref-type="table">Table 2</xref>, <xref ref-type="fig" rid="fig1">Figures 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>). The overall toxicity is depicted in <xref rid="tbl3" ref-type="table">Table 3</xref>. The most frequent toxic therapy effects were haematological (grade 3 toxicity in seven patients, anaemia in three and neutropenia in four.) Severe diarrhoea was present in 2 patients. No grade 4 toxicity was reported. The L-OHP-related peripheral neuropathy appeared to be mild and reversible in the majority of cases. No severe cardiac toxicity or death among the patients was recorded during the study.</p></sec><sec><title>DISCUSSION</title><p>Gastric cancer remains a major cause of cancer death worldwide, with a very poor prognosis in patients with advanced disease. Even though chemotherapy is found to be more beneficial than supportive care alone in patients with advanced or metastatic disease, a standard chemotherapy regimen for gastric cancer has not yet been established. Among antiblastic agents, 5-FU is widely used, but the poor response in patients with advanced stage disease suggests its use it in association with other antiblastic agents. Several combination therapies that have reported satisfactory results in a phase II study were not confirmed in a randomised controlled context. Recently, L-OHP, a third-generation DDP-derived molecule, showed to be effective in the treatment of disease relapse after 5-FU treatment (<xref ref-type="other" rid="bib10">Machover <italic>et al</italic>, 1996</xref>) with a reported response rate in gastro-intestinal tract malignancies ranging from 10 to 20&#x00025;. The combination of L-OHP with 5-FU has been found to be effective in advanced stage with a mild to moderate toxicity (<xref ref-type="other" rid="bib2">De Vita <italic>et al</italic>, 2005</xref>; <xref ref-type="other" rid="bib8">Lordick <italic>et al</italic>, 2005</xref>). Moreover, the use of L-OHP may be helpful in overcoming drug resistance-related therapy drawbacks as its molecule does not share the same action mechanism of DDP.</p><p>In the present study, we administered in a 3-week-based regimen the combination of L-OHP&#x02013;5FU/LV&#x02013;EPI as first-line therapy to patients with locally advanced, recurrent or metastatic gastric cancer. The overall response rate in our patient group was high, as 16 out of the 35 patients that completed the study had an objective response (46&#x00025;), and two of them had a complete response (6&#x00025;). The median time to progression was 33 weeks (8.2 months), with an OS of 49 weeks (12.2 months). The high median survival time did not appear correlated with <italic>a priori</italic> criteria in patient selection, as most patients (58&#x00025;) had a metastatic disease at the beginning of the study and 60&#x00025; of these had multiple metastatic localisations. The results of recent studies using different DDP- or L-OHP-based regimens reported in <xref rid="tbl4" ref-type="table">Table 4</xref> show that efficacy and tolerability are better than in other studies using anthracyclines (<xref ref-type="other" rid="bib9">Macdonald <italic>et al</italic>, 1979</xref>; <xref ref-type="other" rid="bib14">Preusser <italic>et al</italic>, 1989</xref>; In <xref ref-type="other" rid="bib20">Woo <italic>et al</italic>, 2005</xref>). The L-OHP&#x02013;5FU/LV&#x02013;EPI regimen was better tolerated even when compared with other treatment schedules in which 5-FU is used as a single agent or in combination (<xref ref-type="other" rid="bib8">Lordick <italic>et al</italic>, 2005</xref>). Haematological toxicity was characterised by grade 3 anaemia and neutropaenia and was present in 9 and 11&#x00025; of patients, respectively. As L-OHP-related acute peripheral neuropathy was generally mild, short-lived and completely reversible within a few hours, treatment was not discontinued. Cumulative sensory neurotoxicity was present only in 6&#x00025; of patients. Furthermore, L-OHP-induced neurotoxicity was reversible, with a median time to recovery of 12 weeks from grade 3 toxicity. As previously reported by <xref ref-type="other" rid="bib2">De Vita <italic>et al</italic> (2005)</xref>, this study confirms that the low incidence of cumulative sensory neurotoxicity could be related to the rather low L-OHP median cumulative dose received by each patient (530&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>).</p><p>The current study suggests that the combination therapy L-OHP&#x02013;5FU/LV&#x02013;EPI is an active regimen in advanced gastric cancer that has the advantage of being well-tolerated and more easily administered in an outpatients setting. Further randomised controlled studies are mandatory to compare efficacy of this therapy with other association therapies. We do believe that the association L-OHP&#x02013;5FU/LV&#x02013;EPI could improve prognosis and the survival of patients with advanced stage gastric cancer.</p></sec></body><back><ack><p>We thank Professor Grazia Cini for his assistatnce in editing the paper. The study was partially funded by the &#x02018;Associazione Toscana Ricerche e Cure Oncologiche'.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al Batran</surname><given-names>SE</given-names></name><name><surname>Atmaca</surname><given-names>A</given-names></name><name><surname>Hegewisch-Becher</surname><given-names>S</given-names></name></person-group><article-title>Phase II trial of biweekly infusional fluorouracile, folinic acid, and oxaliplatin in patients with advanced gastric cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>658</fpage><lpage>663</lpage><!--PubMed citation query: 'J Clin Oncol||22|658||bib1|'--><pub-id pub-id-type="pmid">14966088</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Vita</surname><given-names>F</given-names></name><name><surname>Orditura</surname><given-names>M</given-names></name><name><surname>Matano</surname><given-names>E</given-names></name><name><surname>Bianco</surname><given-names>R</given-names></name><name><surname>Carlomagno</surname><given-names>C</given-names></name><name><surname>Infusino</surname><given-names>S</given-names></name><name><surname>Damiano</surname><given-names>V</given-names></name><name><surname>Simeone</surname><given-names>E</given-names></name><name><surname>Diadema</surname><given-names>MR</given-names></name><name><surname>Lieto</surname><given-names>E</given-names></name><name><surname>Castellano</surname><given-names>P</given-names></name><name><surname>Pepe</surname><given-names>S</given-names></name><name><surname>De Placido</surname><given-names>S</given-names></name><name><surname>Galizia</surname><given-names>G</given-names></name><name><surname>Di Martino</surname><given-names>N</given-names></name><name><surname>Ciardiello</surname><given-names>F</given-names></name><name><surname>Catalano</surname><given-names>G</given-names></name><name><surname>Bianca</surname><given-names>AR</given-names></name></person-group><article-title>A phase II study biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment, of advanced gastric cancer patients</article-title><source>Br J Cancer</source><year>2005</year><volume>26</volume><fpage>1644</fpage><lpage>1649</lpage><!--PubMed citation query: 'Br J Cancer||26|1644||bib2|'--></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Extra</surname><given-names>JM</given-names></name><name><surname>Marthy</surname><given-names>M</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Misset</surname><given-names>JL</given-names></name></person-group><article-title>Pharmacokinetics and safety profile of oxaliplatin</article-title><source>Semin Oncol</source><year>1998</year><volume>25</volume><supplement>2</supplement><fpage>13</fpage><lpage>22</lpage><!--PubMed citation query: 'Semin Oncol||25|13||bib3|'--></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Meyer</surname><given-names>P</given-names></name></person-group><article-title>Non-parametric estimation for incomplete observations</article-title><source>J Am Stat Assoc</source><year>1958</year><volume>53</volume><fpage>357</fpage><lpage>481</lpage><!--PubMed citation query: 'J Am Stat Assoc||53|357||bib4|'--></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Launchbury</surname><given-names>AP</given-names></name><name><surname>Habboubi</surname><given-names>N</given-names></name></person-group><article-title>Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity</article-title><source>Cancer Treat Rev</source><year>1993</year><volume>19</volume><fpage>197</fpage><lpage>201</lpage><!--PubMed citation query: 'Cancer Treat Rev||19|197||bib5|'--><pub-id pub-id-type="pmid">8334677</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Kwon</surname><given-names>JM</given-names></name><name><surname>Oh</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>HR</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>BB</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Han</surname><given-names>MJ</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name></person-group><article-title>Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/lecovorin in patients with untreated metastatic gastric adenocarcinoma</article-title><source>Ann Oncol</source><year>2007</year><volume>18</volume><fpage>88</fpage><lpage>92</lpage><!--PubMed citation query: 'Ann Oncol||18|88||bib6|'--><pub-id pub-id-type="pmid">16971670</pub-id></citation></ref><ref id="bib7"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Lentner</surname><given-names>C</given-names></name></person-group><article-title>Exact confidence limits</article-title><source>Geigy Scientific Tables</source><year>1982</year><publisher-name>Ciba Geigy: Switzerland</publisher-name><fpage>89</fpage><lpage>102</lpage>Charlotte Lentnere, Anthony Wink (eds)</citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Lorenzen</surname><given-names>S</given-names></name><name><surname>Stollfuss</surname><given-names>J</given-names></name><name><surname>Vehling-Kaiser</surname><given-names>U</given-names></name><name><surname>Kullmann</surname><given-names>F</given-names></name><name><surname>Hentrich</surname><given-names>M</given-names></name><name><surname>Zumschlinge</surname><given-names>R</given-names></name><name><surname>Dietzfelbinger</surname><given-names>H</given-names></name><name><surname>Thoedtmann</surname><given-names>J</given-names></name><name><surname>Henning</surname><given-names>M</given-names></name><name><surname>Seroneit</surname><given-names>T</given-names></name><name><surname>Duyster</surname><given-names>J</given-names></name><name><surname>Peshel</surname><given-names>C</given-names></name><name><surname>Bredenkamp</surname><given-names>R</given-names></name></person-group><article-title>Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid as first-line treatment in metastatic gastric cancer</article-title><source>Br J Cancer</source><year>2005</year><volume>93</volume><fpage>190</fpage><lpage>194</lpage><!--PubMed citation query: 'Br J Cancer||93|190||bib8|'--><pub-id pub-id-type="pmid">16012522</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>JS</given-names></name><name><surname>Wooley</surname><given-names>PV</given-names></name><name><surname>Smythe</surname><given-names>T</given-names></name><name><surname>Ueno</surname><given-names>W</given-names></name><name><surname>Hoth</surname><given-names>D</given-names></name><name><surname>Schein</surname><given-names>PS</given-names></name></person-group><article-title>5-Fluorouracil, adriamycin and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer</article-title><source>Cancer</source><year>1979</year><volume>44</volume><fpage>42</fpage><lpage>47</lpage><!--PubMed citation query: 'Cancer||44|42||bib9|'--><pub-id pub-id-type="pmid">455263</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Machover</surname><given-names>D</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Schift</surname><given-names>A</given-names></name><name><surname>Gastiaburu</surname><given-names>JJ</given-names></name><name><surname>Brienza</surname><given-names>S</given-names></name><name><surname>Itzhaki</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>G</given-names></name><name><surname>N'Daw</surname><given-names>D</given-names></name><name><surname>Vignoud</surname><given-names>J</given-names></name><name><surname>Abad</surname><given-names>A</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Marty</surname><given-names>M</given-names></name><name><surname>Sastre</surname><given-names>J</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name></person-group><article-title>Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines</article-title><source>Ann Oncol</source><year>1996</year><volume>7</volume><fpage>95</fpage><lpage>98</lpage><!--PubMed citation query: 'Ann Oncol||7|95||bib10|'--></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Misset</surname><given-names>JL</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><name><surname>Sutherland</surname><given-names>W</given-names></name><name><surname>Bekradda</surname><given-names>M</given-names></name><name><surname>Cvitkovic</surname><given-names>E</given-names></name></person-group><article-title>Oxaliplatin clinical activity. A review</article-title><source>Crit Rev Oncol Hematol</source><year>2000</year><volume>35</volume><fpage>75</fpage><lpage>93</lpage><!--PubMed citation query: 'Crit Rev Oncol Hematol||35|75||bib11|'--><pub-id pub-id-type="pmid">10936465</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Ryoo</surname><given-names>BY</given-names></name><name><surname>Yang</surname><given-names>SH</given-names></name></person-group><article-title>A phase II study of capecitabine plus 3 weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer</article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><supplement>7</supplement><fpage>959</fpage><lpage>963</lpage><!--PubMed citation query: 'Br J Cancer||94|959||bib12|'--><pub-id pub-id-type="pmid">16552439</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Estimating the World Cancer Burden: GLOBOCAN 2000</article-title><source>Int J Cancer</source><year>2001</year><volume>94</volume><fpage>153</fpage><lpage>156</lpage><!--PubMed citation query: 'Int J Cancer||94|153||bib13|'--><pub-id pub-id-type="pmid">11668491</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Preusser</surname><given-names>P</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Achterrath</surname><given-names>W</given-names></name><name><surname>Fink</surname><given-names>U</given-names></name><name><surname>Lenaz</surname><given-names>L</given-names></name><name><surname>Heinicke</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>HJ</given-names></name><name><surname>Buente</surname><given-names>H</given-names></name></person-group><article-title>Etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><fpage>1310</fpage><lpage>1317</lpage><!--PubMed citation query: 'J Clin Oncol||7|1310||bib14|'--><pub-id pub-id-type="pmid">2671287</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>E</given-names></name><name><surname>Chaney</surname><given-names>SG</given-names></name><name><surname>Taamma</surname><given-names>A</given-names></name><name><surname>Cvitkovic</surname><given-names>E</given-names></name></person-group><article-title>Oxaliplatin: a review of preclinical and clinical studies</article-title><source>Ann Oncol</source><year>1998</year><volume>9</volume><fpage>1</fpage><lpage>19</lpage><!--PubMed citation query: 'Ann Oncol||9|1||bib15|'--></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>R</given-names></name></person-group><article-title>Optimal two-stage designs for phase II clinical trials</article-title><source>Control Clin Trials</source><year>1989</year><volume>10</volume><fpage>1</fpage><lpage>10</lpage><!--PubMed citation query: 'Control Clin Trials||10|1||bib16|'--><pub-id pub-id-type="pmid">2702835</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thuss-Patience</surname><given-names>PC</given-names></name><name><surname>Kretzchmar</surname><given-names>A</given-names></name><name><surname>Repp</surname><given-names>M</given-names></name><name><surname>Kingreen</surname><given-names>D</given-names></name><name><surname>Hennesser</surname><given-names>D</given-names></name><name><surname>Micheel</surname><given-names>S</given-names></name><name><surname>Pink</surname><given-names>D</given-names></name><name><surname>Scholz</surname><given-names>C</given-names></name><name><surname>Dorken</surname><given-names>B</given-names></name><name><surname>Reichardt</surname><given-names>P</given-names></name></person-group><article-title>Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin and fluorouracil for advanced gastric adenocarcinama: a randomized phase II study</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><supplement>3</supplement><fpage>494</fpage><lpage>501</lpage><!--PubMed citation query: 'J Clin Oncol||23|494||bib17|'--><pub-id pub-id-type="pmid">15659494</pub-id></citation></ref><ref id="bib18"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>AD</given-names></name><name><surname>Grothe</surname><given-names>W</given-names></name><name><surname>Behl</surname><given-names>S</given-names></name><name><surname>Kleber</surname><given-names>G</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Haerting</surname><given-names>J</given-names></name><name><surname>Fleig</surname><given-names>WE</given-names></name></person-group><article-title>Chemotherapy for advanced gastric cancer</article-title><source>Cochrane Database of Systematic Reviews</source><year>2005</year>Issue 2 Art. No. CD004064. DOI: 10.1002/4651858.CD004064.pub2</citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Preusser</surname><given-names>P</given-names></name><name><surname>Fink</surname><given-names>U</given-names></name><name><surname>Achterrath</surname><given-names>W</given-names></name><name><surname>Meyer</surname><given-names>HJ</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Lenaz</surname><given-names>L</given-names></name><name><surname>Siewert</surname><given-names>JR</given-names></name><name><surname>Geerlings</surname><given-names>H</given-names></name></person-group><article-title>New developments in the treatment of gastric carcinoma</article-title><source>Semin Oncol</source><year>1991</year><volume>17</volume><fpage>61</fpage><lpage>70</lpage><!--PubMed citation query: 'Semin Oncol||17|61||bib19|'--><pub-id pub-id-type="pmid">2305269</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>IS</given-names></name><name><surname>Moon</surname><given-names>DH</given-names></name><name><surname>Shim</surname><given-names>BY</given-names></name><name><surname>Lee</surname><given-names>MA</given-names></name><name><surname>Byun</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Kang</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>MG</given-names></name><name><surname>Chung</surname><given-names>IS</given-names></name><name><surname>Hong</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name></person-group><article-title>A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma</article-title><source>Jpn J Clin Oncol</source><year>2005</year><volume>35</volume><supplement>1</supplement><fpage>13</fpage><lpage>17</lpage><!--PubMed citation query: 'Jpn J Clin Oncol||35|13||bib20|'--><pub-id pub-id-type="pmid">15681598</pub-id></citation></ref><ref id="bib21"><citation citation-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title/><source>Handbook for Reporting Results of Cancer Treatment</source><year>1979</year><publisher-name>Geneva</publisher-name>W.H.O offset publication No.48.</citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Kaplan&#x02013;Meier estimates of time to progression among patients with gastric cancer treated with oxaliplatin, 5-fluorouracil/leucovorin and epirubicin regimen.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="eps" xlink:href="6603644f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Kaplan&#x02013;Meier estimates of OS among patients with gastric cancer treated with oxaliplatin, 5-fluorouracil/leucovorin and epirubicin regimen.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="eps" xlink:href="6603644f2"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>No. of patients</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Enrolled/evaluable</td><td align="center" valign="top" charoff="50">36/35</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Gender</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="center" valign="top" charoff="50">25 (70&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="center" valign="top" charoff="50">11 (30&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Age</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Mean</td><td align="center" valign="top" charoff="50">58 years</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Range</td><td align="center" valign="top" charoff="50">39&#x02013;72 years</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Performance status</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 0</td><td align="center" valign="top" charoff="50">9 (25&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 1</td><td align="center" valign="top" charoff="50">20 (56&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Grade 2</td><td align="center" valign="top" charoff="50">6 (17&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Disease stage</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Locally advanced or recurrent</td><td align="center" valign="top" charoff="50">15 (42&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Metastatic</td><td align="center" valign="top" charoff="50">21 (58&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Number of metastatic sites</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="center" valign="top" charoff="50">10 (50&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="center" valign="top" charoff="50">7 (33&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="center" valign="top" charoff="50">4 (17&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Metastasis localisation</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Liver</td><td align="center" valign="top" charoff="50">12</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Nodes</td><td align="center" valign="top" charoff="50">9</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Peritoneal</td><td align="center" valign="top" charoff="50">8</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lung</td><td align="center" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Bone</td><td align="center" valign="top" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Ovarian</td><td align="center" valign="top" charoff="50">1</td></tr></tbody></table></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Response to treatment</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Evaluable patients no.</bold></th><th align="center" valign="top" charoff="50"><bold>35</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Number of cycles</td><td align="center" valign="top" charoff="50">185</td></tr><tr><td align="left" valign="top" charoff="50">Mean cycles/patient</td><td align="center" valign="top" charoff="50">5.3</td></tr><tr><td align="left" valign="top" charoff="50">Range</td><td align="center" valign="top" charoff="50">2&#x02013;7</td></tr><tr><td align="left" valign="top" charoff="50">CR</td><td align="center" valign="top" charoff="50">2 (6&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">PR</td><td align="center" valign="top" charoff="50">14 (40&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">Stable Disease:</td><td align="center" valign="top" charoff="50">13 (37&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">Progression of disease</td><td align="center" valign="top" charoff="50">6 (17&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">Overall response rate (CR&#x0002b;PR)</td><td align="center" valign="top" charoff="50">16 (46&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">Median time to progression (weeks)</td><td align="center" valign="top" charoff="50">33 (6&#x02013;104&#x0002b;)</td></tr><tr><td align="left" valign="top" charoff="50">Median response duration (weeks)</td><td align="center" valign="top" charoff="50">27 (7&#x02013;104&#x0002b;)</td></tr><tr><td align="left" valign="top" charoff="50">Median survival (weeks)</td><td align="center" valign="top" charoff="50">49 (9&#x02013;104&#x0002b;)</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><label/><p>CR=complete response; PR=partial response.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Toxicities</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>WHO Grade</bold></th><th align="center" valign="top" charoff="50"><bold>1</bold></th><th align="center" valign="top" charoff="50"><bold>2</bold></th><th align="center" valign="top" charoff="50"><bold>3</bold></th><th align="center" valign="top" charoff="50"><bold>4</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Anaemia</td><td align="center" valign="top" charoff="50">22 (62&#x00025;)</td><td align="center" valign="top" charoff="50">10 (29&#x00025;)</td><td align="center" valign="top" charoff="50">3 (9&#x00025;)</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Neutropaenia</td><td align="center" valign="top" charoff="50">17 (49&#x00025;)</td><td align="center" valign="top" charoff="50">14 (40&#x00025;)</td><td align="center" valign="top" charoff="50">4 (11&#x00025;)</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Thrombocitopenia</td><td align="center" valign="top" charoff="50">23 (65&#x00025;)</td><td align="center" valign="top" charoff="50">11 (32&#x00025;)</td><td align="center" valign="top" charoff="50">1 (3&#x00025;)</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Anorexia</td><td align="center" valign="top" charoff="50">24 (68&#x00025;)</td><td align="center" valign="top" charoff="50">11 (32&#x00025;)</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Nausea</td><td align="center" valign="top" charoff="50">22 (62&#x00025;)</td><td align="center" valign="top" charoff="50">13 (38&#x00025;)</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Vomiting</td><td align="center" valign="top" charoff="50">21 (60&#x00025;)</td><td align="center" valign="top" charoff="50">14 (40&#x00025;)</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhoea</td><td align="center" valign="top" charoff="50">19 (54&#x00025;)</td><td align="center" valign="top" charoff="50">14 (40&#x00025;)</td><td align="center" valign="top" charoff="50">2 (6&#x00025;)</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Stomatitis</td><td align="center" valign="top" charoff="50">24 (68&#x00025;)</td><td align="center" valign="top" charoff="50">11 (32&#x00025;)</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Neurotoxicity</td><td align="center" valign="top" charoff="50">20 (56&#x00025;)</td><td align="center" valign="top" charoff="50">13 (38&#x00025;)</td><td align="center" valign="top" charoff="50">2 (6&#x00025;)</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr></tbody></table></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p content-type="table-title">Results of DDP- or L-OHP-based regimens in advanced gastric cancer</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Study</bold></th><th align="center" valign="top" charoff="50"><bold>No. patients</bold></th><th align="left" valign="top" charoff="50"><bold>Regimen</bold></th><th align="center" valign="top" charoff="50"><bold>Overall response rate (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Median TTP (months)</bold></th><th align="center" valign="top" charoff="50"><bold>Median OS (months)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><xref ref-type="other" rid="bib1">Al Batran <italic>et al</italic> (2004)</xref>, <italic>J Clin Oncol</italic></td><td align="center" valign="top" charoff="50">41</td><td align="left" valign="top" charoff="50">L-OHP/5-FU</td><td align="center" valign="top" charoff="50">43</td><td align="center" valign="top" charoff="50">5.6</td><td align="center" valign="top" charoff="50">9.6</td></tr><tr><td align="left" valign="top" charoff="50"><xref ref-type="other" rid="bib2">De Vita <italic>et al</italic> (2005)</xref>, <italic>Br J Cancer</italic></td><td align="center" valign="top" charoff="50">61</td><td align="left" valign="top" charoff="50">L-OHP/5-FU</td><td align="center" valign="top" charoff="50">45</td><td align="center" valign="top" charoff="50">7.1</td><td align="center" valign="top" charoff="50">11.2</td></tr><tr><td align="left" valign="top" charoff="50"><xref ref-type="other" rid="bib8">Lordick <italic>et al</italic> (2005)</xref>, <italic>Br J Cancer</italic></td><td align="center" valign="top" charoff="50">48</td><td align="left" valign="top" charoff="50">L-OHP/5-FU</td><td align="center" valign="top" charoff="50">48</td><td align="center" valign="top" charoff="50">6.5</td><td align="center" valign="top" charoff="50">11.4</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Leucovorin</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><xref ref-type="other" rid="bib17">Thuss-Patience <italic>et al</italic> (2005)</xref>, <italic>J Clin Oncol</italic></td><td align="center" valign="top" charoff="50">45</td><td align="left" valign="top" charoff="50">EPI/DDP/5-FU</td><td align="center" valign="top" charoff="50">37</td><td align="center" valign="top" charoff="50">5.5</td><td align="center" valign="top" charoff="50">9.5</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">45</td><td align="left" valign="top" charoff="50">Docetaxel/5-FU</td><td align="center" valign="top" charoff="50">35</td><td align="center" valign="top" charoff="50">5.3</td><td align="center" valign="top" charoff="50">9.7</td></tr><tr><td align="left" valign="top" charoff="50"><xref ref-type="other" rid="bib20">Woo <italic>et al</italic> (2005)</xref>, <italic>Jpn J Clin Oncol</italic></td><td align="center" valign="top" charoff="50">35</td><td align="left" valign="top" charoff="50">EPI/DDP/tegafur</td><td align="center" valign="top" charoff="50">41</td><td align="center" valign="top" charoff="50">5.1</td><td align="center" valign="top" charoff="50">8.1</td></tr><tr><td align="left" valign="top" charoff="50"><xref ref-type="other" rid="bib6">Lee <italic>et al</italic> (2007)</xref>, <italic>Ann Oncol</italic></td><td align="center" valign="top" charoff="50">48</td><td align="left" valign="top" charoff="50">L-OHP/CPT-11/5-FU</td><td align="center" valign="top" charoff="50">66</td><td align="center" valign="top" charoff="50">9.6</td><td align="center" valign="top" charoff="50">14.8</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Leucovorin</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><xref ref-type="other" rid="bib12">Park <italic>et al</italic> (2006)</xref>, <italic>Br J Cancer</italic></td><td align="center" valign="top" charoff="50">20</td><td align="left" valign="top" charoff="50">L-OHP/capecitabine</td><td align="center" valign="top" charoff="50">65</td><td align="center" valign="top" charoff="50">7.5</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><label/><p>DPP=cisplatin; EPI=epirubicin; 5-FU=5-fluorouracil; L-OHP=oxaliplatin.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


